ALUR SEC申報文件 - Allurion Technologies Inc.-年度報告，委任書，招股章程

基本數據

CIK

1964979

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Allurion Technologies Inc.

SEC Filings (Chronological Order)

本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。

May 27, 2026	EX-16.1	May 27, 2026 Exhibit 16.1 May 27, 2026 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Allurion Technologies, Inc.'s Form 8-K dated May 27, 2026, and have the following comments: 1. We agree with the statements made in the section titled “Dismissal of Independent Registered Public Accounting Firm”. 2. We have no basis on which to agr
May 27, 2026	8-K	FORM 8-K Item 4.01 Changes in Registrant’s Certifying Accountant. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2026 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commissio
May 15, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41767 Allurion Technologies, Inc.
March 30, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41767 Allurion Techno
March 12, 2026	8-K	FORM 8-K Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2026 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commiss
March 12, 2026	EX-99.1	Allurion Advances Plan to Regain Listing Compliance Files appeal to NYSE on decision to initiate delisting proceedings Company’s recent FDA approval catalyzes plan to regain compliance with the continued listing requirements of NYSE or initial listin Exhibit 99.1 Allurion Advances Plan to Regain Listing Compliance Files appeal to NYSE on decision to initiate delisting proceedings Company’s recent FDA approval catalyzes plan to regain compliance with the continued listing requirements of NYSE or initial listing requirements of the NYSE American NATICK, Mass. – March 12, 2026 – Allurion Technologies, Inc. (the “Company”) (OTCID: ALUR), a pioneer
March 2, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 ALLURION TECHNOLOGI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commissi
March 2, 2026	EX-99.1	Allurion Intends to Appeal NYSE Notice of Delisting While Executing Plan to Regain Compliance and Expects to Remain Trading EX-99.1 Exhibit 99.1 Allurion Intends to Appeal NYSE Notice of Delisting While Executing Plan to Regain Compliance and Expects to Remain Trading Company’s recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process NATICK, Mass. – March 2, 2026 – Allurion Technologie
February 25, 2026	EX-10.1	allurion technologies, inc. Exhibit 10.1 allurion technologies, inc. February 24, 2026 To: Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Allurion Technologies, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.
February 25, 2026	EX-4.1	COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS, AND, ACCORDINGLY, MAY NOT BE O
February 25, 2026	8-K	FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. Item 3.02 Unregistered Sales of Equity Securities. Item 3.03 Material Modification to Rights of Security Holders. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Comm
February 23, 2026	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Comm
February 23, 2026	EX-99.1	Allurion Receives U.S. FDA Approval for the Allurion Gastric Balloon System, Featuring the Allurion Smart Capsule Approval provides Allurion with access to approximately 80 million Americans with obesity Exhibit 99.1 Allurion Receives U.S. FDA Approval for the Allurion Gastric Balloon System, Featuring the Allurion Smart Capsule Approval provides Allurion with access to approximately 80 million Americans with obesity NATICK, Mass. – February 23, 2026 – Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and Drug Administratio
January 20, 2026	424B3	ALLURION TECHNOLOGIES, INC. Up to 5,988,024 Shares of Common Stock 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-292660 PROSPECTUS ALLURION TECHNOLOGIES, INC. Up to 5,988,024 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by the selling securityholders identified in this prospectus of up to an aggregate of 5,988,024 shares of common stock, par value $0.0001 per share (“common stock”
January 12, 2026	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commi
January 12, 2026	EX-99.1	Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results Strong quarter-over-quarter revenue growth with continued, substantial improvement in operating expenses and operating loss Exhibit 99.1 Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results Strong quarter-over-quarter revenue growth with continued, substantial improvement in operating expenses and operating loss NATICK, Mass. – January 12, 2026 – Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced preliminary, unaudited results for the fourth qua
January 9, 2026	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 ALLURION TECHNOLOGIES, INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward
January 9, 2026	S-3	As filed with the Securities and Exchange Commission on January 9, 2026 S-3 Table of Contents As filed with the Securities and Exchange Commission on January 9, 2026 Registration No.
December 29, 2025	POS AM	As filed with the Securities and Exchange Commission on December 29, 2025 POS AM Table of Contents As filed with the Securities and Exchange Commission on December 29, 2025 Registration No.
December 22, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 22 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 22 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which fo
December 22, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 31 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 31 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) whic
December 19, 2025	8-K	FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Comm
November 25, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
November 24, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-4
November 24, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
November 18, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 30 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 30 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the
November 18, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 21 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 21 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Pro
November 17, 2025	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition P
November 17, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41767 Allurion Technologies, Inc.
November 17, 2025	EX-10.4	Assignment of Lease and Consent to Assignment, dated as of July 10, 2025, by and among Allurion Technologies, Inc., Aila Technologies Inc., and 3 Huron Investments, LLC. Exhibit 10.4 Assignment of Lease and Consent to Assignment, dated as of July 10, 2025, by and among Allurion Technologies, Inc., Aila Technologies Inc., and 3 Huron Investments, LLC. This ASSIGNMENT OF LEASE AND CONSENT TO ASSIGNMENT (this“Agreement”) is dated for reference purposes only as July 10th, 2025, and is by and among Allurion Technologies, Inc., a Delaware corporation (“Assignor”), Aila
November 14, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
November 12, 2025	EX-10.3	SECURITIES PURCHASE AND EXCHANGE AGREEMENT by and among ALLURION TECHNOLOGIES, INC., RTW INNOVATION MASTER FUND LTD., RTW BIOTECH OPPORTUNITIES OPERATING LTD RTW MASTER FUND, LTD. November 11, 2025 EX-10.3 Exhibit 10.3 Execution Version SECURITIES PURCHASE AND EXCHANGE AGREEMENT by and among ALLURION TECHNOLOGIES, INC., RTW INNOVATION MASTER FUND LTD., RTW BIOTECH OPPORTUNITIES OPERATING LTD and RTW MASTER FUND, LTD. November 11, 2025 This Securities Purchase and Exchange Agreement contains a number of representations and warranties which the Company and the Purchasers have made to each othe
November 12, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 29 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 29 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) whic
November 12, 2025	EX-4.1	COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: [___] Issue Date: November __, 2025 EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AND, ACCORDINGLY, MAY NO
November 12, 2025	EX-3.1	CERTIFICATE OF DESIGNATIONS SERIES B PERPETUAL CONVERTIBLE PREFERRED STOCK ALLURION TECHNOLOGIES, INC. EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES B PERPETUAL CONVERTIBLE PREFERRED STOCK OF ALLURION TECHNOLOGIES, INC. The undersigned, Shantanu Gaur, Chief Executive Officer of Allurion Technologies, Inc. (the “Company”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify, in accordance with Sections 103 and 1
November 12, 2025	EX-99.1	Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update NATICK, Mass. – November 12, 2025 – Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update. Recent Company Highlights • Successfully passed U.S. Food and Drug Administrat
November 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 ALLURION TECHNOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commi
November 12, 2025	EX-10.1	SECURITIES PURCHASE AGREEMENT EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 11, 2025, between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms
November 12, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 20 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 20 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which fo
November 12, 2025	EX-10.2	REGISTRATION RIGHTS AGREEMENT EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of November 11, 2025, between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Sec
November 12, 2025	EX-99.2	Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing Passing of key audits with zero findings and co EX-99.2 Exhibit 99.2 Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing Passing of key audits with zero findings and completion of Day-100 meeting are significant milestones in the FDA PMA process as the Company enters final stages of FDA review pr
October 6, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 28 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 28 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) whic
October 6, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 19 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 19 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which fo
October 3, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 Allurion Techn UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Com
August 28, 2025	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No.
August 28, 2025	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No.
August 28, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-4
August 28, 2025	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No.
August 21, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 18 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 18 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Pro
August 21, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 27 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 27 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the
August 21, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 17 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 17 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Pro
August 21, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 26 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 26 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the
August 19, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-4
August 19, 2025	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No.
August 19, 2025	EX-4.4	Description of Capital Stock. Exhibit 4.4 DESCRIPTION OF SECURITIES The following summary of the material terms of Allurion Technologies, Inc.’s (“Allurion”, the “Company”, “we”, or “our”) securities is not intended to be a complete summary of the rights and preferences of such securities. You are encouraged to read the applicable provisions of Delaware law, Allurion’s certificate of incorporation (“Charter”) and bylaws in the
August 19, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41767 Allurion Technologies, Inc.
August 19, 2025	EX-10.7	Eighth Amendment to 11 Huron Lease, dated as of June 20, 2025, by and between Allurion Technologies, Inc. and Legacy Huron, LLC. Exhibit 10.7 EIGHTH AMENDMENT TO LEASE Legacy Huron, LLC, LESSOR and Allurion Technologies, Inc., LESSEE Reference is hereby made to a Lease dated June 15, 2016, as amended by the “First Amendment” to Lease dated as of November, 2016, as amended by the “Second Amendment” to lease dated March 20, 2017, as amended by the “Third Amendment” to Lease dated June 21, 2017, as amended by the “Fourth Amend
August 15, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 16 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 16 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which fo
August 15, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 25 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 25 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) whic
August 15, 2025	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Tra
August 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Allurion Technolo UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis
August 13, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis
August 13, 2025	EX-99.1	Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update NATICK, Mass. – August 13, 2025 – Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. Recent Company Highlights and Outlook • Announced new strategic direction focused on l
August 7, 2025	EX-99.1	Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry Signed term sheet with strategic partner to enhance distribution capabilities and R&D pipeline, inclu Exhibit 99.1 Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry Signed term sheet with strategic partner to enhance distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting balloon Submitted protocol to IRBs for approval on prospective, multi
August 7, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 15 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 15 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which fo
August 7, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 2.05 Costs Associated with Exit or Disposal Activities. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis
August 7, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 24 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 24 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) whic
June 18, 2025	EX-FILING FEES	Calculation of Filing Fee Table Form S-8 (Form Type) Allurion Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Allurion Technologies, Inc.
June 18, 2025	S-8	As filed with the Securities and Exchange Commission on June 18, 2025 As filed with the Securities and Exchange Commission on June 18, 2025 Registration No.
May 20, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 14 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 14 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectu
May 20, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 23 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 23 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41767 Allurion Technologies, Inc.
May 14, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commissio
May 14, 2025	EX-99.1	Allurion Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Allurion Reports First Quarter 2025 Financial Results and Provides Business Update NATICK, Mass.—May 14, 2025 — (BUSINESS WIRE) — Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook • Maint
May 7, 2025	CORRESP	VIA EDGAR CORRESP VIA EDGAR May 7, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
May 6, 2025	LETTER	LETTER May 6, 2025 Shantanu Gaur Chief Executive Officer Allurion Technologies, Inc. 11 Huron Drive Natick, MA 01760 Re: Allurion Technologies, Inc. Registration Statement on Form S-3 Filed April 30, 2025 File No. 333-286837 Dear Shantanu Gaur: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accelera
April 30, 2025	EX-FILING FEES	Filing Fee Table. EX-FILING FEES EXHIBIT 107 Form S-3 (Form Type) Allurion Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly
April 30, 2025	S-3	As filed with the Securities and Exchange Commission on April 29, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 29, 2025 Registration No.
April 18, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 13 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 13 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms pa
April 18, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 22 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 22 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form
April 17, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commiss
April 17, 2025	EX-10.1	Second Amendment to Note Purchase Agreement, dated as of April 15, 2025, by and among Allurion Technologies, Inc., the purchasers party thereto, and RTW Investments, LP, as agent for the purchasers. Exhibit 10.1 SECOND AMENDMENT TO NOTE PURCHASE AGREEMENT This Second Amendment to Note Purchase Agreement (this “Amendment”), dated as of April 15, 2025, is among Allurion Technologies, Inc., a Delaware corporation (together with its successors and permitted assigns, the “Company”), the purchasers party to the Existing Note Purchase Agreement (as defined below), each, a “Purchaser” and, collective
April 11, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 21 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 21 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form
April 11, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 12 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 12 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms pa
April 10, 2025	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commiss
April 3, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 3, 2025	EX-99.1	Allurion Announces Postponement of Special Meeting of Stockholders Meeting to Now be Held on Thursday, April 10, 2025 at 12:00 pm Via Live Audio Webcast EX-99.1 Exhibit 99.1 Allurion Announces Postponement of Special Meeting of Stockholders Meeting to Now be Held on Thursday, April 10, 2025 at 12:00 pm Via Live Audio Webcast NATICK, Mass. – April 3, 2025 – Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the “Special Meeting”), o
April 3, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commissi
March 27, 2025	EX-97.1	Allurion Technologies, Inc. Compensation Recovery Policy. Exhibit 97.1 ALLURION TECHNOLOGIES, INC. COMPENSATION RECOVERY POLICY Adopted as of July 31, 2023 Allurion Technologies, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Per
March 27, 2025	EX-19.1	Allurion Technologies, Inc. Insider Trading Policy. Exhibit 19.1 ALLURION TECHNOLOGIES, INC. INSIDER TRADING POLICY This memorandum sets forth the policy of Allurion Technologies, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider tra
March 27, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41767 Allurion Techno
March 27, 2025	EX-4.4	Description of Capital Stock. Exhibit 4.4 DESCRIPTION OF SECURITIES The following summary of the material terms of Allurion Technologies, Inc.’s (“Allurion”, the “Company”, “we”, or “our”) securities is not intended to be a complete summary of the rights and preferences of such securities. You are encouraged to read the applicable provisions of Delaware law, Allurion’s certificate of incorporation (“Charter”) and bylaws in the
March 27, 2025	EX-21.1	List of subsidiaries of Allurion Technologies Holdings, Inc. Exhibit 21.1 Subsidiaries of Allurion Technologies, Inc. Name of Subsidiary Jurisdiction of Incorporation Allurion France SAS France Allurion Middle East Medical Instrument Trading LLC United Arab Emirates Allurion UK Ltd. United Kingdom Allurion Italy,Srl Italy Allurion Spain, Srl Spain Allurion Australia Pty Ltd. Australia Allurion Mexico S. de R.L de C.V. Mexico Allurion Technologies, LLC. Dela
March 26, 2025	EX-99.1	Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update NATICK, Mass.
March 26, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commiss
March 24, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 13, 2025	PRER14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
February 28, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1
February 26, 2025	EX-99.1	ALUR / Allurion Technologies Inc. / Leavitt Equity Partners III, L.P. - EX-99.1 EC<\YEQ3[3:"S" \$'BO 7@-WD+X/PASGT-$X;R!,!^ M],3!0 begin 644 ck0001669811-ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5AF4@,S8F)D8!!@ M8&)@8.H!D0Q^())Q#8AD5@:3O6#91#"["LPV!)/M8%(53#X$ZTH"D8OW@$4* MP;% 4G&H(M \O^G&PQ,0+MF@L49&(DBS,PWO\)$& 1%(/)0T96YD9VQF8%D4QZZR!\1F. , T4T)T T96YD7!E+U!A9V4^/@UE;F1O8FH-,3,@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C M;V1E+T9I/8M%IU7][6;>K,V35%M3N9K M'$QA]Z?DQFRUC;[D]&ZOC.G)'G<[4JS=7/#7UR%M)[-)XM\1YZ3R.2V&!K M@(Y1
February 21, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 20 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 20 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form
February 21, 2025	EX-99.2	Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline Exhibit 99.2 Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline NATICK, Mass. – Feb. 20, 2025 – Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering with institutional investors for the purchase and
February 21, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 11 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 11 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms pa
February 21, 2025	EX-99.1	Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline Exhibit 99.1 Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline NATICK, Mass., February 19, 2025—(BUSINESS WIRE)—Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement
February 21, 2025	EX-10.1	Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 19, 2025, between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con
February 21, 2025	EX-10.2	Subscription Agreement, dated as of February 19, 2025, between Allurion Technologies, Inc. and the investors named therein. Exhibit 10.2 SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of February 19, 2025, is made by and among Allurion Technologies, Inc., a Delaware corporation (the “Company”) and the Investor set forth on Schedule I (“Investor”). WHEREAS, the Company desires to sell, and Investor desires to purchase from the Company, shares of its common stock, par value $0.0001 per share (the “Common Stock”) and
February 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 ALLURION TECHNO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Comm
February 21, 2025	EX-4.1	Form of Common Warrant (February 2025). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
February 21, 2025	EX-1.1	Placement Agency Agreement, dated as of February 19, 2025, by and between Allurion Technologies, Inc. and Roth Capital Partners, LLC. Exhibit 1.1 PLACEMENT AGENCY AGREEMENT February 19, 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Allurion Technologies, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $6,107,000 of securities of the Company,
February 21, 2025	EX-4.2	Form of Private Placement Warrant (February 2025). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
February 20, 2025	424B5	ALLURION TECHNOLOGIES, INC. 900,000 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-283721 PROSPECTUS SUPPLEMENT (To Prospectus dated December 20, 2024) ALLURION TECHNOLOGIES, INC. 900,000 Shares of Common Stock We are offering 900,000 shares of our common stock to certain accredited investors, at an offering price of $5.23 per share and accompanying common warrant (as defined below). In a concurrent private
February 14, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 19 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 19 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form
February 14, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 10 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 10 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms pa
February 13, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Comm
February 13, 2025	EX-99.1	Allurion Relaunches in France Exhibit 99.1 Allurion Relaunches in France ANSM, the French regulatory authority, clears Allurion to resume sales of the Allurion Balloon Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss February 13, 2025 08:30 AM Eastern Standard Time NATICK, Mass.—(BUSINESS WIRE)—Allurion Technologies, Inc. (“Allurion” or the “Com
January 29, 2025	EX-99.20	ALUR.WS / Allurion Technologies Inc. - Equity Warrant / RTW INVESTMENTS, LP - EX-99.20 begin 644 ck0001669811-ex9920.pdf M)5!$1BTQ+C<"C0@,"!O8FH$ED96YT:71Y0IE;F1O8FH-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@-C7!E("]3=')E86T M/CX<[%T+0%15^O.O?."F6%FD)> VY9;K=MK7;.VQXCFHKGEEK759K7IMKTSL]=N5MO? MWLG]?^?<.\/,@(J-=KY7>YWON<\S.=U[W#O<" 8 H)!IHS2[F[;[II=R M03LZ!2#^RFG9.;E1'\8N!N'6:@"Q=%K!G)T6^33(-RV"X2HL&E%V7WEA M!VA<^P"N>&U&47'NLF$U.
January 28, 2025	EX-4.1	Form of Common Warrant (January 2025). EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
January 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 ALLURION TECHNOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commi
January 28, 2025	EX-10.1	Securities Purchase Agreement, dated as of January 24, 2025, by and between Allurion Technologies, Inc. and the purchasers named therein. EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 24, 2025, between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms
January 28, 2025	EX-99.1	Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market EX-99.1 Exhibit 99.1 Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market NATICK, Mass. – Jan. 24, 2025 – Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase an
January 28, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 18 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 18 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form
January 28, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 9 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms part
January 28, 2025	EX-1.1	Placement Agency Agreement, dated as of January 24, 2025, by and between Allurion Technologies, Inc. and Roth Capital Partners, LLC. Exhibit 1.1 PLACEMENT AGENCY AGREEMENT January 24, 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Allurion Technologies, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $7,440,000 of securities of the Company, includ
January 27, 2025	424B5	ALLURION TECHNOLOGIES, INC. 1,240,000 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-283721 PROSPECTUS SUPPLEMENT (To Prospectus dated December 20, 2024) ALLURION TECHNOLOGIES, INC. 1,240,000 Shares of Common Stock We are offering 1,240,000 shares of our common stock to certain accredited investors, at an offering price of $6.00 per share and accompanying common warrant (as defined below). In a concurrent priv
January 17, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 8 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms part
January 17, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 ALLURION TECHNOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commi
January 17, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 17 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 17 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form
January 17, 2025	EX-10.1	Subscription Agreement, dated as of January 14, 2025, between Allurion Technologies, Inc. and the investors named therein. Exhibit 10.1 SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of January 14, 2025, is made by and among Allurion Technologies, Inc., a Delaware corporation (the “Company”) and the Investors set forth on Schedule I (the “Investors”). WHEREAS, the Company desires to sell and the Investors desire to purchase from the Company shares of its common stock, par value $0.0001 per share (the “Common Stoc
January 17, 2025	EX-99.1	Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024 Exhibit 99.1 Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024 NATICK, Mass. – Jan. 14, 2025 – Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Invest
January 16, 2025	EX-99.19	ALUR.WS / Allurion Technologies Inc. - Equity Warrant / RTW INVESTMENTS, LP - EX-99.19 begin 644 ck0001669811-ex9919.pdf M)5!$1BTQ+C<-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A M9V4O4&%R96YT(#(@,"!2+U)E7!E+T=R;W5P+U,O5')A M;G-P87)E;F-Y+T-3+T1E=FEC95)'0CX^+U1A8G,O4R]3=')U8W1087)E;G1S M(# ^/@T96YD;V)J#0HT(# @;V)J#0H\/"]&:6QT97(O1FQA=&5$96-O9&4O M3&5N9W1H(#4S,S(^/@TO7J[*)M)W7KJ^AL6\CEKU=1= VO/R15[$2:HCI>-" M1ED1IWDDDKC0.EK/7K[XU]^CZN6+)SYV>?ORQ=D;$>5QHJ/;^Y??73R]?#&Z&(MD=#668G
January 14, 2025	RW	Allurion Technologies, Inc. 11 Huron Drive Natick, MA 01760 Allurion Technologies, Inc. 11 Huron Drive Natick, MA 01760 January 14, 2025 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Re: Allurion Technologies, Inc.—Request for Withdrawal of Registration Statement on Form S-1 (File No. 333-283701) Ladies and Gentlemen: Pursuant to Rule 477 promulgate
January 13, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Allurion Technologies, Inc.
January 13, 2025	EX-10.48	Form of Securities Purchase Agreement. Exhibit 10.48 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January , 2025, between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond
January 13, 2025	S-1/A	As filed with the Securities and Exchange Commission on January 13 , 2025. Registration No. 333-283701 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT Table of Contents As filed with the Securities and Exchange Commission on January 13 , 2025.
January 13, 2025	EX-4.5	Form of Series A Common Warrant. Exhibit 4.5 SERIES A COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: [ ] Issue Date: [ ], 2025 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the
January 13, 2025	EX-1.1	Form of Placement Agency Agreement. Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [ ], 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Allurion Technologies, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $[ ] of registered securities of the Company, in
January 13, 2025	EX-4.6	Form of Series B Common Warrant. Exhibit 4.6 SERIES B COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: [] Issue Date: [], 2025 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder
January 8, 2025	EX-99.2	INDEX TO FINANCIAL STATEMENTS ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES Page Interim Unaudited Financial Statements as of September 30, 2024 Unaudited Condensed Consolidated Balance Sheets F-2 Unaudited Condensed Consolidated Statements of Operati Exhibit 99.2 INDEX TO FINANCIAL STATEMENTS ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES Page Interim Unaudited Financial Statements as of September 30, 2024 Unaudited Condensed Consolidated Balance Sheets F-2 Unaudited Condensed Consolidated Statements of Operations F-3 Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) F-4 Unaudited Condensed Consolidated Statements of Sto
January 8, 2025	EX-1.1	Form of Placement Agency Agreement. Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [ ], 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Allurion Technologies, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $[ ] of registered securities of the Company, in
January 8, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Allurion Technologies, Inc.
January 8, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 7 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which form
January 8, 2025	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation
January 8, 2025	S-1/A	As filed with the Securities and Exchange Commission on January 8 , 2025. Registration No. 333-283701 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT Table of Contents As filed with the Securities and Exchange Commission on January 8 , 2025.
January 8, 2025	EX-4.6	Form of Pre-Funded Warrant. Exhibit 4.6 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o
January 8, 2025	EX-99.1	INDEX TO FINANCIAL STATEMENTS ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES Page Audited Consolidated Financial Statements as of December 31, 2023 Report of Independent Registered Public Accounting Firm (PCAOB ID: 34) F-2 Consolidated Balance Sheets a Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES Page Audited Consolidated Financial Statements as of December 31, 2023 Report of Independent Registered Public Accounting Firm (PCAOB ID: 34) F-2 Consolidated Balance Sheets as of December 31, 2023 and 2022 F-3 Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022 F-4 Consolidated
January 8, 2025	EX-10.48	Form of Securities Purchase Agreement. Exhibit 10.48 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January , 2025, between Allurion Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond
January 8, 2025	EX-4.5	Form of Warrant. Exhibit 4.5 COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: [] Initial Exercise Date: [], 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “
January 8, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 16 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 16 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) whic
January 8, 2025	EX-10.49	Omnibus Amendment, dated as of January 7, 2025, by and among Allurion Technologies, Inc., Allurion Technologies, LLC, Allurion Australia Pty Ltd, Allurion France, RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Biotech Opportunities Operating Ltd., and RTW Investments, LP. Exhibit 10.49 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) IS OF THE TYPE THAT THE REGISTRANT TREATS AS CONFIDENTIAL, THE DISCLOSURE OF WHICH WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY. OMNIBUS AMENDMENT This Omnibus Amendment, dated as of Ja
January 8, 2025	EX-99.3	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.3 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis includes information that our management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. The discussion and analysis should be read together with the consolidated financial statements as o
January 8, 2025	EX-99.4	Allurion Announces Positive Topline Results From AUDACITY Trial At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favor Exhibit 99.4 Allurion Announces Positive Topline Results From AUDACITY Trial At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable safety profile of the Allurion Balloon Fourth and final module of PMA submission including AUDACITY trial data planned for 2025 NATI
January 7, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 15 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 15 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) whic
January 7, 2025	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 6 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which form
January 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 ALLURIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporatio
December 31, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 14 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 14 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form
December 31, 2024	EX-99.1	Allurion Technologies, Inc. Announces Reverse Stock Split Exhibit 99.1 Allurion Technologies, Inc. Announces Reverse Stock Split NATICK, Mass., December 24, 2024 (GLOBE NEWSWIRE) – Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company’s common stock, par value $0.0001 per sh
December 31, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 ALLURIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporatio
December 31, 2024	EX-3.1	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Allurion Technologies, Inc. EX-3.1 2 d924855dex31.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALLURION TECHNOLOGIES, INC. ALLURION TECHNOLOGIES, INC., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Allurion Technologies, Inc. The date of the filing of it
December 31, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 5 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms part
December 20, 2024	POS AM	As filed with the Securities and Exchange Commission on December 20, 2024 Table of Contents As filed with the Securities and Exchange Commission on December 20, 2024 Registration No.
December 19, 2024	CORRESP	VIA EDGAR VIA EDGAR December 19, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
December 19, 2024	S-3/A	As filed with the Securities and Exchange Commission on December 19, 2024 S-3/A As filed with the Securities and Exchange Commission on December 19, 2024 Registration No.
December 19, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 4 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms part
December 19, 2024	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Allurion Technologies, Inc.
December 19, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 12 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 12 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms
December 19, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 13 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 13 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form
December 18, 2024	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Comm
December 16, 2024	LETTER	LETTER December 16, 2024 Shantanu Gaur Chief Executive Officer Allurion Technologies, Inc.
December 10, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Allurion Technologies, Inc.
December 10, 2024	S-3	As filed with the Securities and Exchange Commission on December 10, 2024 Table of Contents As filed with the Securities and Exchange Commission on December 10, 2024 Registration No.
December 10, 2024	S-1	Power of Attorney (included on signature page to this Registration Statement). As filed with the Securities and Exchange Commission on December 9, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 92-2182207 (State or other jurisdiction of incorporation or organiz
December 10, 2024	EX-4.8	Form of indenture for senior debt securities and the related form of senior debt security. EX-4.8 Exhibit 4.8 ALLURION TECHNOLOGIES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trus
December 10, 2024	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Allurion Technologies, Inc.
December 10, 2024	EX-4.9	Form of indenture for subordinated debt securities and the related form of subordinated debt security. EX-4.9 Exhibit 4.9 ALLURION TECHNOLOGIES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities an
November 14, 2024	SC 13G/A	ALUR / Allurion Technologies Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-alur093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Allurion Technologies, Inc. (Name of Issuer) Common Stock, par value, $0.0001 per share (Title of Class of Securities) 02008G102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen
November 14, 2024	SC 13G/A	ALUR / Allurion Technologies Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427061d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Allurion Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shar
November 14, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 11 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 11 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospe
November 14, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 12 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 12 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prosp
November 14, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 3 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”
November 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Comm
November 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Comm
November 13, 2024	EX-99.1	Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update NATICK, Mass.- November 13, 2024 - (BUSINESS WIRE) - Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Recent Company Highligh
November 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41767 Allurion Technologies, Inc.
November 8, 2024	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41767 Allurion Techno
November 8, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
November 5, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 10 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 10 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which
November 5, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 11 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 11 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form
November 5, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 2 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 2 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, the “Prospectus”) which forms part
November 4, 2024	EX-10.1	Revenue Interest Financing Agreement, dated as of October 30, 2024, by and among Allurion Technologies, LLC, RTW Master Fund Ltd., RTW Innovation Master Fund, Ltd. and RTW Biotech Opportunities Operating Ltd. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on November 4, 2024). Execution Version Exhibit 10.1 REVENUE INTEREST FINANCING AGREEMENT among ALLURION TECHNOLOGIES, LLC and RTW MASTER FUND, LTD., RTW INNOVATION MASTER FUND, LTD., and RTW BIOTECH OPPORTUNITIES OPERATING LTD Dated as of October 30, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION 1 Section 1.1 Defined Terms 1 Section 1.2 Rules of Construction 34 ARTICLE II REVENUE INTERE
November 4, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commi
October 29, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 10 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 10 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which form
October 29, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock 424B3 1 d872151d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279902 Prospectus Supplement No. 1 (To Prospectus dated October 7, 2024) ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) amends and supplements the prospectus dated October 7, 2024 (as supplemented or amended from time to time, th
October 29, 2024	424B3	ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock 424B3 1 d872151d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-280466 Prospectus Supplement No. 5 (To Prospectus dated June 28, 2024) ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated June 28, 202
October 29, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 9 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p
October 28, 2024	8-K	Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commi
October 28, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
October 24, 2024	SC 13D/A	ALUR / Allurion Technologies Inc. / RTW INVESTMENTS, LP - ALLURION TECHNOLOGIES INC. Activist Investment SC 13D/A 1 p24-3055sc13da.htm ALLURION TECHNOLOGIES INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 3) Under the Securities Exchange Act of 1934 ALLURION TECHNOLOGIES, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 02008G102 (CUSIP Number) RTW Investments, LP Attn: Roderick Wong, M.D. 40 10th
October 7, 2024	424B5	ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-279902 PROSPECTUS ALLURION TECHNOLOGIES, INC. Up to 65,211,325 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by the selling securityholder identified in this prospectus of up to an aggregate of 65,211,325 shares of common stock, par value $0.0001 per share (“common stock”), of
October 3, 2024	S-1/A	As filed with the Securities and Exchange Commission on October 3, 2024 Registration No. 333-279902 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF As filed with the Securities and Exchange Commission on October 3, 2024 Registration No.
October 3, 2024	CORRESP	VIA EDGAR VIA EDGAR October 3, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
September 30, 2024	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 Form S-1 (Form Type) Allurion Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Newly Registered Sec
September 30, 2024	S-1/A	As filed with the Securities and Exchange Commission on September 30, 2024 Registration No. 333-279902 UNITED STATE S SECURITIES AND EXCHANGE COMMISSIO N Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES A Table of Contents As filed with the Securities and Exchange Commission on September 30, 2024 Registration No.
September 6, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 9 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms
September 6, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 8 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p
September 6, 2024	424B3	ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-280466 Prospectus Supplement No. 4 (To Prospectus dated June 28, 2024) ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) amends and supplements the prospectus dated June 28, 2024 (as supplemented or amended fr
September 5, 2024	EX-99.1	Allurion Receives Continued Listing Standards Notice from NYSE Exhibit 99.1 Allurion Receives Continued Listing Standards Notice from NYSE September 5, 2024 NATICK, Mass.-(BUSINESS WIRE)- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued
September 5, 2024	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis
September 4, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 02, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Com
September 4, 2024	EX-99.1	Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Exhibit 99.1 Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market NATICK, Mass. – Sep. 3, 2024 – Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of D
August 16, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 8 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms
August 16, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 7 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p
August 16, 2024	424B3	ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-280466 Prospectus Supplement No. 3 (To Prospectus dated June 28, 2024) ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) amends and supplements the prospectus dated June 28, 2024 (as supplemented or amended fr
August 15, 2024	EX-99.1	Allurion Receives Continued Listing Standards Notice from NYSE Exhibit 99.1 Allurion Receives Continued Listing Standards Notice from NYSE August 15, 2024 NATICK, Mass.-(BUSINESS WIRE)- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued li
August 15, 2024	8-K	Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis
August 15, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 6 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospect
August 15, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 7 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospec
August 15, 2024	424B3	ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280466 Prospectus Supplement No. 2 (To Prospectus dated June 28, 2024) ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock This prospectus supplement no. 2 (this “Prospectus Supplement”) amends and supplements the prospectus dated June 28, 2024 (as suppleme
August 14, 2024	EX-10.7	Offer Letter dated May 17, 2024 with Ojas Buch (incorporated by reference to Exhibit 10.7 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024). Exhibit 10.7 17 May 2024 Mr. Ojas Buch [***] Re: Conditional Offer of Employment with Allurion Technologies, Inc. Dear Ojas, It is with great pleasure that we offer you the position of Chief Operating Officer with Allurion Technologies, Inc. (the “Company”). You will be reporting to Shantanu Gaur, CEO & Founder, and your anticipated start date is Monday, 3 June 2024. You will work in our Natick, M
August 14, 2024	EX-10.6	Eighth Amendment to 14 Huron Lease, dates as of April 3, 2024, by and between Allurion Technologies, Inc. and Fourteen Huron Drive, LLC (incorporated by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024). Exhibit 10.6 EIGHTH AMENDMENT TO LEASE THIS EIGHTH AMENDMENT TO LEASE (the "8th Amendment") is made and entered into as of April 3, 2024 (the "Execution Date"), by and between FOURTEEN HURON DRIVE, LLC, a Massachusetts limited liability company ("Landlord''), and ALLURION TECHNOLOGIES, INC., a Delaware corporation ("Tenant"). RECITALS A. Landlord and Tenant arc parties to that certain lease dated
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41767 Allurion Technologies, Inc.
August 13, 2024	EX-99.1	Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update Results highlighted by strong sequential revenue growth and record procedure volume Exhibit 99.1 Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update Results highlighted by strong sequential revenue growth and record procedure volume NATICK, Mass.- August 13, 2024 - (BUSINESS WIRE) - Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the second quar
August 13, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis
August 9, 2024	SC 13G	ALUR / Allurion Technologies Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
August 8, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 6 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms
August 8, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 5 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p
August 8, 2024	424B3	ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-280466 Prospectus Supplement No. 1 (To Prospectus dated June 28, 2024) ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) amends and supplements the prospectus dated June 28, 2024 (as supplemented or amended fr
August 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 Allurion Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State or Other Jurisdiction of Incorporation) (Commis
July 5, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 5 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms
July 5, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 4 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p
July 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 ALLURION TECHNOLOGIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commissio
July 2, 2024	SC 13D/A	ALUR / Allurion Technologies Inc. / RTW INVESTMENTS, LP - ALLURION TECHNOLOGIES INC. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 ALLURION TECHNOLOGIES, INC. (formerly known as Allurion Technologies Holdings, Inc.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 02008G102 (CUSIP Number) RTW Investments, LP Attn: Roderick Wong, M.D. 40 10th
July 1, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-276131 Prospectus Supplement No. 3 (To Prospectus dated December 29, 2023) ALLURION TECHNOLOGIES, INC. Up to 9,482,468 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 29, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms p
July 1, 2024	EX-1.1	Underwriting Agreement, dated as of June 28, 2024, among Allurion Technologies, Inc., Jefferies LLC and TD Securities (USA) LLC, as representatives of the underwriters named therein. Exhibit 1.1 Execution Version ALLURION TECHNOLOGIES, INC. UNDERWRITING AGREEMENT June 28, 2024 JEFFERIES LLC TD SECURITIES (USA) LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o TD SECURITIES (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Introductory. Allurion Technologies, Inc., a Delaware corporati
July 1, 2024	EX-3.1	Certificate of Designations of Preferences Rights and Limitations of Series A Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 1, 2024). Exhibit 3.1 ALLURION TECHNOLOGIES, INC. CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Allurion Technologies, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly
July 1, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41767 92-2182207 (State or other jurisdiction of incorporation) (Commissi
July 1, 2024	EX-4.2	Form of Private Placement Warrant. Exhibit 4.2 COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 20 Issue Date: July 1, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, to subscribe for and purchase f
July 1, 2024	EX-4.1	Form of Public Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 1, 2024). Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ALLURION TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 20 Issue Date: July 1, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, to subscribe for and purchase f
July 1, 2024	EX-99.1	Allurion Announces Pricing of $20 Million Public Offering and Concurrent Private Placement June 28, 2024 Exhibit 99.1 Allurion Announces Pricing of $20 Million Public Offering and Concurrent Private Placement June 28, 2024 NATICK, Mass., June 28, 2024 (BUSINESS WIRE) – Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the pricing of an underwritten public offering of 14,406,508 shares of its common stock, par value $0.0001 p
July 1, 2024	EX-10.1	Subscription Agreement, dated as of June 28 2024, between Allurion Technologies, Inc. and the investors named therein (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 1, 2024). Exhibit 10.1 EXECUTION VERSION SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of June 28, 2024, is made by and among Allurion Technologies, Inc., a Delaware corporation (the “Company”) and the Investors set forth on Schedule I (the “Investors”). WHEREAS, concurrently with this Agreement, the Company is entering into an Underwriting Agreement (as amended or modified from time to time, the “Und
July 1, 2024	424B3	ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-274564 Prospectus Supplement No. 4 (To Prospectus dated December 15, 2023) ALLURION TECHNOLOGIES, INC. Up to 56,548,268 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the “Prospectus”) which forms
June 28, 2024	424B4	ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-280466 PROSPECTUS ALLURION TECHNOLOGIES, INC. 14,406,508 Shares of Common Stock Warrants to Purchase up to 14,406,508 Shares of Common Stock We are offering 14,406,508 of shares of our common stock and new warrants to purchase up to an aggregate of 14,406,508 shares of our common stock. This prospectus also relates to the offe
June 26, 2024	S-1	As filed with the Securities and Exchange Commission on June 25, 2024. Registration No. 333- UN ITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALLURION TECHN As filed with the Securities and Exchange Commission on June 25, 2024. Registration No. 333- UN ITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALLURION TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 92-2182207 (State or other jurisdiction of incorporation or organiz
June 26, 2024	EX-4.5	Form of Warrant Agreement. Exhibit 4.5 WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”), dated as of , 2024, is entered into by and between Allurion Technologies, Inc. a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as Warrant Agent. Section 1. Definitions. In addition to the terms defined elsewhere in this Warrant Agreement, the following terms have
June 26, 2024	EX-1.1	Form of Underwriting Agreement. Exhibit 1.1 ALLURION TECHNOLOGIES, INC. UNDERWRITING AGREEMENT [Date] JEFFERIES LLC TD SECURITIES (USA) LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o TD SECURITIES (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Introductory. Allurion Technologies, Inc., a Delaware corporation (the “Company”), propo
June 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Allurion Technologi UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Allurion Technologies, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-41767 92-2182207 (State of Incorporation or Organization) (Commission Fil
June 26, 2024	EX-4.6	Form of Warrant. Exhibit 4.6 [Form of Warrant Certificate] [FACE] Number Warrants THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE WARRANT AGREEMENT DESCRIBED BELOW ALLURION TECHNOLOGIES, INC. Incorporated Under the Laws of the State of Delaware CUSIP [ ] Warrant Certificate This Warrant Certificate certifies that, or registered assigns, is the register
June 26, 2024	EX-99.1	1 Disclaimer This presentation, the information contained herein and the materials accompanying it (together, this “presentation”) contains confidential, material and non-public information regarding Allurion Technologies, Inc. (the “Company” or “us” Exhibit 99.1 Investor Presentation 1 Disclaimer This presentation, the information contained herein and the materials accompanying it (together, this “presentation”) contains confidential, material and non-public information regarding Allurion Technologies, Inc. (the “Company” or “us”) and is provided to the recipients (“you”) of this presentation on the condition that you agree to hold it in stri
June 26, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Allurion Technologies, Inc.
June 25, 2024	CORRESP	VIA EDGAR VIA EDGAR June 26, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
June 25, 2024	CORRESP	[signature page follows] June 26, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
June 21, 2024	POS AM	As filed with the Securities and Exchange Commission on June 21, 2024 Registration No. 333-276131 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECU Table of Contents As filed with the Securities and Exchange Commission on June 21, 2024 Registration No.

ALUR / Allurion Technologies Inc. - SEC申報文件，年度報告，委任書

基本數據

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?